A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

104

Participants

Timeline

Start Date

August 17, 2022

Primary Completion Date

February 28, 2026

Study Completion Date

February 28, 2026

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

JAB 21822

Administered orally

Trial Locations (21)

100010

NOT_YET_RECRUITING

Research site08, Beijing

NOT_YET_RECRUITING

Research site09, Beijing

100032

NOT_YET_RECRUITING

Research site021, Beijing

100089

NOT_YET_RECRUITING

Research site02, Beijing

100101

RECRUITING

Research site01, Beijing

101100

NOT_YET_RECRUITING

Research site013, Beijing

110000

NOT_YET_RECRUITING

Research site06, Shenyang

NOT_YET_RECRUITING

Research site07, Shenyang

130000

NOT_YET_RECRUITING

Research site015, Changchun

150000

NOT_YET_RECRUITING

Research site018, Harbin

310000

NOT_YET_RECRUITING

Research site019, Hangzhou

361000

NOT_YET_RECRUITING

Research site05, Xiamen

400000

NOT_YET_RECRUITING

Research site010, Chongqing

410000

NOT_YET_RECRUITING

Research site012, Changsha

430060

NOT_YET_RECRUITING

Research site03, Hubei

450000

NOT_YET_RECRUITING

Research site04, Zhengzhou

518000

NOT_YET_RECRUITING

Research site011, Shenzhen

530000

NOT_YET_RECRUITING

Research site016, Nanning

710000

NOT_YET_RECRUITING

Research site020, Xi’an

050000

NOT_YET_RECRUITING

Research site017, Shijiazhuang

010000

NOT_YET_RECRUITING

Research site014, Hohhot

Sponsors
All Listed Sponsors
lead

Allist Pharmaceuticals, Inc.

INDUSTRY

NCT05276726 - A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1 | Biotech Hunter | Biotech Hunter